Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year collaboration with ...

Merck’s MRK stock has risen 32.3% in the past three months. The stock has also been trading above its 50-day and 200-day ...

Merck is in talks to acquire Revolution Medicines in a deal that could value it at around $30 billion, according to people ...

The company’s previous CCO was Cristal Downing, who joined Insulet as chief corporate affairs officer late last year.

Merck is in talks to buy cancer drug developer Revolution Medicines in a $28 billion to $32 billion deal, the Financial Times ...

Merck CEO Rob Davis expressed high confidence during the company’s J.P. Morgan presentation on Monday, revealing that the ...

US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of ...

Merck stock surges 30% on strong fundamentals, regulatory catalysts, and attractive valuation. See why I rate the MRK stock a ...

A key number for Merck in the coming years is $70 billion. This is the mid-2030s revenue opportunity from potential new ...

RAHWAY, N.J. - Merck is officially adding an experimental flu prevention drug to its portfolio. The New Jersey-based ...

Rumors of a Revolution buyout come as the industry gears up for one of its biggest trade conferences, where observers expect ...

Registration for Merck Forest & Farmland Center’s 2026 summer camps will open at 9 a.m. on Jan. 26, inviting children to ...